Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

titute
  • Location: Ernest N. Morial Convention Center, Hall E.
  • Additional Abstracts

    In addition to the abstract accepted for presentation, two additional abstracts describing  EphA3 expression and screening in myeloid malignancies were accepted for publication online and in the ASH conference materials. These abstracts outline An Immunohistochemistry (IHC) Screen For EphA3 Positive Tumors and Analysis of EphA3 Expression in Hematologic Malignancies by Quantitative PCR.

    "These published abstracts further detail our ongoing research efforts on EphA3," stated Dr. Geoffrey Yarranton, Chief Scientific Officer and Executive Vice President of Research and Development at KaloBios. "We continue to work to understand EphA3 expression on various tumor types, and we now have a validated EphA3 screening test operative at a CLIA laboratory to screen patients' tumor biopsies before entry into the Phase 2 portion of Study KB004-01 in AML and MDS."

    About KaloBios

    KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

    Currently, KaloBios has three drug development programs:

    • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a Phase 2 study in the United States, Europe and Australia.
    • KB001-A, an anti-PcrV mAb fragment that is partnered exclusively with Sanofi Pasteur and is being developed for the prevention and treatment of Pa infections. KaloBios has retained right
      '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology news :

    1. Cell therapy using patients own bone marrow may present option for heart disease
    2. Report presents designs for study of cancer risks near US nuclear facilities
    3. Entomology 2012 to present 105 insect symposia in November
    4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
    5. The Brain Prize 2012 is presented May 9th
    6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
    7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
    8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
    9. Coral reef experts to present latest coral reef science during July symposium
    10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
    11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
    (Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
    (Date:2/5/2015)... Jan. 26, 2015   Epic Sciences , a precision ... announced that Murali Prahalad , Ph.D., president and CEO, ... Conference (PMWC) 2015: Silicon Valley, which is taking place ... Calif. on January 26-28, 2015. ... Age as Biomarkers." Last year, Epic Sciences was a finalist ...
    Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
    ... tens of thousands of manual lab experiments, two University ... to cut the development time of new antibiotics. While ... a computerized modeling system being developed at UH will ... professor of clinical sciences, and Michael Nikolaou, professor of ...
    ... stem cell lines grown and banked at the University ... ready for worldwide distribution to researchers working on discovering ... diabetes, Alzheimer,s and Parkinson,s, among others. Stem cells ... ability to not only renew themselves for long periods, ...
    ... that first discovered tumor-associated RNA in tiny membrane-enclosed sacs ... found that these microvesicles also contain segments of tumor ... that copy and insert themselves into other areas of ... published in Nature Communications, is the first ...
    Cached Biology News:Team hopes to cut years off development time of new antibiotics 2UMASS Medical School's human stem cell bank makes available first seven stem cell lines 2UMASS Medical School's human stem cell bank makes available first seven stem cell lines 3Tumor microvesicles reveal detailed genetic information 2
    (Date:3/5/2015)... FRANCISCO , March 5, 2015  Twelve patients ... six-way kidney paired donation transplant at California Pacific Medical ... Physicians here believe this procedure will be the largest ... Coast and the largest conducted in the 44-year history ... today and tomorrow began with an altruistic donor who ...
    (Date:3/5/2015)... 2015 BioPlus Specialty Pharmacy (BioPlus) announces ... Vice President of Managed Care. In this role, Damm ... of the nation’s leading specialty pharmacies. , Damm, who ... of specialty pharmacy and biotech experience to his new ... Vertex Pharmaceuticals, and Pfizer. Prior to working in Healthcare ...
    (Date:3/5/2015)... , March 5, 2015  UBM Medica ... , a leading online community to help oncologists ... the newest information available regarding the use of ... kidney cancer. March is National ... very few effective adjuvant treatment options for renal ...
    (Date:3/5/2015)... Cleveleys (UK) (PRWEB) March 05, 2015 ... implantable polymer have received the CE mark (European) approval. ... the European Free Trade Association (EFTA) and the European ... mark has now been granted to implants supplied by ... disc spinal conditions. , Osimplant's Cervical Expandable Bladed ...
    Breaking Biology Technology:Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 2Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 3Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3
    ... OSAKA, Japan, Oct. 17 Affymax,Inc. (Nasdaq: ... 4502),today announced that they have been awarded the ... Society of the U.S. and Canada (LES),for their ... product candidate, Hematide(TM), for the treatment of,anemia. The ...
    ... to empower transplant patients ... and ... US,Inc. (Pink Sheets: ALPMF), a leader in the field of ... organization, announced a collaborative partnership to jointly,develop further materials for ...
    ... Oct. 17 /PRNewswire-FirstCall/ - Botaneco, a business unit ... has reached an,agreement with AVAC Ltd. for $2.4 ... as an independent business. The funding will be,paid ... the fourth,quarter of 2007, upon the formation of ...
    Cached Biology Technology:Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 3Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3Botaneco obtains $2.4 million in funding from AVAC 2Botaneco obtains $2.4 million in funding from AVAC 3
    Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
    MDMA Mouse Monoclonal Antibody (Clone 3G8)...
    ... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
    ... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_005544 ... Routinely evaluated by immunoblot. ...
    Biology Products: